SCHEMBL14897467

SCHEMBL14897467

Cc1nc2ccc(-c3ccccc3C(F)(F)F)nn2c1C(=O)Nc1cc(N2CCCC2)ncn1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ CYP1A2 P05177 6/20 0.44
▸ CYP2C19 P33261 4/20 0.44
▸ MPL P40238 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ NPC1 O15118 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ TSHR P16473 3/20 0.40
▸ CYP3A4 P08684 3/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ GBA1 P04062 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ ERBB3 P21860 1/20 0.37
▸ PIK3C3 Q8NEB9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14896854 0.88 PDE10A (0.40) ALDH1A1RAB9ANPC1GBA1KDM4E
SCHEMBL14896724 0.86 CLK2 (0.40) CYP1A2CYP2C19MPLRAB9ANPC1
SCHEMBL16265216 0.85 CYP1A2 (0.38) CYP1A2CYP2C19MPLALDH1A1TSHR
SCHEMBL14897304 0.85 CYP1A2 (0.41) CYP1A2CYP2C19ALDH1A1TSHRCYP3A4
SCHEMBL14896619 0.84 MPL (0.43) CYP1A2CYP2C19MPLTSHRCYP3A4
SCHEMBL16193155 0.82 ATR (0.38) CYP1A2CYP2C19MPLRAB9ANPC1
SCHEMBL14897428 0.82 CHRNB2 (0.43) CYP1A2CYP2C19MPLALDH1A1TSHR
SCHEMBL18655147 0.82 SYK (0.41) MPLGBA1PIK3C3
SCHEMBL14896789 0.81 GRM5 (0.40) SMN1; SMN2MPLALDH1A1RAB9ANPC1
SCHEMBL14896785 0.81 CLK2 (0.49) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 SMN1; SMN2 2001/4885CYP1A2 1236/4885CYP2C19 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback